Background: The present study investigated the patients with Chronic Myeloid Leukemia in chronic phase (CP-CML) who had beenon the first-line Imatinib Mesylate (IM) therapy for a period of 84 months. Materials and Methods: This retrospective study was conducted in 295 newly-diagnosed CP-CML patients(age >18 years)who were admitted to the Hematology, Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran during 1 January 2009 to 30 December 2016. Response to treatment was evaluated by molecular response assessment. Rates of IM dose adjustment, switching to another drug therapy, Progression to Accelerate Phase (AP) and Blastic Crisis (BC) and long-term outcomes included Overall Survival (OS) and Progression Free Survival (PFS) were assesed. Results: Patients' average age was 41.7 years, and 52.9% were male. 44.4% of patients at the month 18 achieved Major Molecular Response (MMR). Progression to AP/BC occurred in 26 patients during 84 months, and the estimated rate of OS and PFS were 71.83 and 74.48, respectively. Among the patients who didn't achieve MMR at month 18 , 61 patients were treated with IM ( 400 mg /day), and then after month 18, 24(39.3%) of whom achieved MMR. Dose adjustments occurred in 60 patients (20.33%). IM dose increases were observed in 53 patients who didn't achive optimal response to imatinib or loss of optimal response. IM dose decreases were observed in 7 patients. 25 (8.47%) patients were switched to a different Tyrosine Kinase Inhibitor (TKI). Most of TKI changes(n=21) happened in patients who didn't achieve optimal response to IM and for the 4 patients TKI changes were owing to adverse events of IM. Among the patients undergoing change in treatment, 24(43.75%) patient achieved MMR. Conclusion: Our data showed the high effectiveness of the change in the treatment of IM-resistant condition. Moreover, our finding suggests that imatinib be effective in Iranian patients after a long period of time compared to the referenced studies.
INTRODUCTION
Chronic myeloid leukemia (CML) is a myeloproliferative disease, characterized by the clonal expansion of pluripotent hematopoietic stem cells with reciprocal translocation between chromosomes 9 and 22 (Philadelphia chromosome). This translocation leads to the formation of the BCR-ABL fusion gene that encodes an active tyrosin kinase and plays a crucial role in the pathophysiology of the CML 1, 2 . Most CML patients are diagnosed at the chronic phase and experience mild symptoms. However the disease can progress to the Accelerated Phases (AP) and Blastic Crisis (BC) which characterized by rising numbers of blast cells in the blood and the bone marrow 2 . CML accounts for 15% of adult's leukemia and its worldwide incidence is between 1.0 and 1.5 per 100,000 3 . CML occurs in all age groups but, the incidence of it increases by age. CML is more common in males than females with a male/female ratio of 1.2-1.7 3, 4 .There is a difference in the median age at diagnosis between developed countries and developing countries. The median age in the developed countries is 57-60 years whereas the median age in developing countries has been reported 32-44 years 5 . The development of Imatinib Mesylate(IM) and other Tyrosine Kinase Inhibitors (TKIs) for the treatment of CML is associated with improved survival.IM was approved by the FDA in May 2001 as the first line of CP-CML treatment and it is the most effective treatmentin the CP phase 2,4,6 . In the International Randomized Study of Interferon and STI571( IRIS) newly diagnosed CP-CML patients treated with IM had an 8-years overall survival (OS) of 83.3%, progression free survival (PFS) of 93%, and eventfree survival (EFS) of 81%. The standard starting dose of IM for the chronic phase is 400 mg/day 7, 8 . Approximately one third of patients show resistance to IM 7, 9 . In these cases, alternative options include increased IM dose to 600 or 800 mg/day and switching to second and third generation TKIs such as Nilotinib and Dasatinib are considered as acceptable approach 4, 6, 10, 11 . In this article, we retrospectively analyzed data from 295 Iranian CP-CML patients. The objective was focused on describing some epidemiologic characteristics, treatment patterns and evaluation of response to the treatment and outcomes efficacy.
MATERIALS AND METHODS Study Patients
This observational retrospective study was conducted using medical records from the Hematology and Oncology Department of Shari'ati Hospital in Tehran. The samples included 295 newly-diagnosed Philadelphiapositive (PH+)CP-CML patients who were admitted, treated and followed up to this hospital between 1January 2010 and 30 September 2016.CP-CML diagnosis was based on European Leukemia Net's (ELN) CML diagnostic criteria 11 . Adult patients (aged≥18) who received first-line therapy with IM after diagnosis were eligible for this study and only prior therapy with Hydroxyurea at initial of prognosis was permitted.Demographics and general characteristics, hematologic analysis, cytogenetical and molecular diagnosis at baseline, molecular assessment at 3, 6, 12, 18 and then at every 6 months, treatment modifications (dose change and drug change)and clinical and laboratory information about disease progression to AP or BC were obtained from medical records.The study was approved by the Ethics Committee of the Shari'ati Hospital.
Evaluation of response to treatment
Standardized quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) method was used to determined BCR-ABL transcript level. The ratio of BCR-ABL to ABL was calculated and reported on the International Scale (IS) 12 . ELN defines the optimal response to treatment as a Major Molecular Response (MMR; BCR-ABL1IS≤ 0.1%) at the month 12 of treatment.Loss of MMR after the month12 is consideredas a failure of treatment by ELN. In the current study, evaluation of response to treatment in patients who didn't had molecular assessment at month12, determined based on the molecular evaluation at month 18.
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Statistical analysis
Categorical and numerical variables were described using numbers and frequencies & medians and ranges respectively. The primary end points of the study were overall survival (OS) and Progression-free survival (PFS). OS was defined as the time from the diagnosis until death from any cause. PFS defined as survival without evidence of accelerated phase (AP) or blast crisis (BC). The Kaplan-Meier method was used to estimate OS and PFS. Statistical analyses were performed using the SPSS version 18 software. (SPSS, Chicago, IL, USA).
RESULTS

Sample Characteristics
A total of 295newly-diagnosed CP-CML patients were enrolled in this retrospective study. Demographic and laboratory characteristics of patients at base line were summarized in Table 2 and 3, respectively.
Discontinuation of treatment and loss of follow-up
Up to end of this study 47 patients didn't refere to this center and lost of follow-up.Becouse an uncertain number of patients referred to other medical centers, the rate of patients who discontinued IM was unclear. 
DISCUSSION
This retrospective observational study described treatment patterns and disease outcomes for 295 adult CP-CML PH+ Iranian patients. The mean age of the patients at the time of diagnosis was 41.7 years .This is similar to result of studies in developing countries that reported the median age at diagnosis between 32 and 44 years old 5 . Moreover, in the current study, the male to female ratio in CML patients was 1.2 and this is in line with other studies that reported this ratio between 1.2 and 1.7 3, 4 . In the present study, all patients received a dose of 400 mg Indian IM per day as the first-line therapeutic regimen. According to ELN and NCCN recommendation, patients who do not achieve MMR or CCyR at month12 (failure to first line IM therapy ) may receive a dose escalation or switch to Second and third generation TKIs 11, 13, 14 . In the current study, only molecular assessment was carried out. Furthermore, the evaluation of response to treatment in patients who didn't had molecular assessment at month12 determined based on the molecular evaluation at month 18. Up to month 18, 131 out of 295 patients achieved MMR . The rate of patients achieving MMR at month 18 was lower compared to referenced clinical trials (44.4% in our data compared to 64.8% in IRIS study) 7 . The low molecular response rate in our study can be due to low adherence of patients to medication, difference of drug brand and difference response to IM treatment. In this study, the estimated overall survival rate and progression-free survival at 84 months with first-line imatinib therapy was 71.83% and 74.48%, respectively, whereas in the international randomized study of interferon and STI (IRIS), OS and PFS were reported to be 88% and 93% at 6 years, respectively and the estimated OS rate at 11 years with first-line imatinib therapy was 83.3% 7, 8 . According to ELN recommendations, patients who do not achieve MMR at 12 months are considered as failures to IM treatment 4, 6, 13 . Switching to second-line TKIs and dose escalation of IM can increase response rates in patients with inadequate response to IM [15] [16] [17] [18] . In this study, among the patients, who didn't achieve MMR at 12 or 18, IM dose escalation and switching to second-line TKIs were observed only in 64 patients. However, it is important to note that most of the patients were diagnosed with CML before 2013, and the change in the treatment of patients was more common in patients who were diagnosed with CML after 2013. Our data showed that among the patients undergoing change in treatment, 24(43.75%) patients achieved MMR.This rate indicates the high effectiveness of the treatment change in IM-resistant patients. IM dose increase and switching to the different TKI didn't occurre in 61 of 153 patients who didn't achieve MMR and treatment with 400 mg of imatinib was continued, and then after month 18, 24 patients (39.3%) achieved MMR. This information suggests that imatinib be effective in Iranian patients after a long period of time compared to referenced studies 6, 19 .
Limitations
Similar to other retrospective studies, there were some limitations to our study. First, there wasn't data available to assess spleen size for numerous of the patients, so we couldn't obtain Sokal score to predict prognosis of the disease. Moreover, there were no hematological data in a large number of patients. Second, the response to imatinib treatment was evaluated through molecular response evaluation and there was no cytogenetic evaluation in vast majority of patients; therefor, we assessed response to imatinib only based on molecular response evaluation. Third, about 40% of patients did not continue to follow imatinib therapy at this center, so there is no information about their outcomes. Finally, the study was based on data from a single center, although this center is a referral center. 
